Announcements
- Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
- New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
- Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
- Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
- Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
- Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
- Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
- Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
- Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health
- Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
More ▼
Key statistics
As of last trade, Myriad Genetics Inc (MYD:DUS) traded at 17.00, 30.77% above the 52 week low of 13.00 set on Oct 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.70 |
---|---|
High | 17.00 |
Low | 16.40 |
Bid | 16.90 |
Offer | 17.20 |
Previous close | 16.60 |
Average volume | 113.33 |
---|---|
Shares outstanding | 90.48m |
Free float | 88.36m |
P/E (TTM) | -- |
Market cap | 1.63bn USD |
EPS (TTM) | -3.20 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 18:31 BST.
More ▼